mpi indium dtpa in 111
Small moleculeapproved
Approved
Feb 18, 1982
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1980s
- Feb 18, 1982
General Electric — Earliest FDA Approval
- Feb 18, 1982
General Electric — NDA Secondary Org
- Feb 18, 1982
General Electric — NDA Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedFeb 18, 1982
Chemistry & pharmacology
- Mol. weight
- 611.29 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Payload
- 111-indium
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL2221313 ↗
- ChEMBLCHEMBL2107480 ↗
Also known as
- indium (111in) pentetate disodium
- indium-111 pentetate (dtpa)
- indium in-111 pentetate
- indium in-111 pentetate disodium
- indium pentetate
- mpi indium dtpa (111in)
- mpi indium dtpa in 111
- pentetate indium disodium (111in)
- pentetate indium disodium in 111
- pentetate indium disodium in 111
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| General Electric | For profit | NDA2 | Feb 18, 1982 |
| General Electric | For profit | NDA | Feb 18, 1982 |